Articles tagged with Chimeric Antigen Receptors
A new SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer, a deadly form of cancer with low five-year survival rate. The team will focus on epigenetics and exploring new therapies targeting mesothelin in pancreatic cancer.
Researchers found genetically modified CAR T cells successfully migrated to and penetrated glioblastoma tumors, but triggered an immunosuppressive tumor microenvironment. To overcome resistance, existing immunotherapies targeting checkpoint inhibitors may be necessary.
A clinical trial of CAR T-cell immunotherapy achieved durable molecular remissions in 71% of patients with chronic lymphocytic leukemia who had failed other treatments. Genetic tracing of cancer cells from bone marrow biopsies showed a better predictor of prognosis than standard lymph node scans.
Researchers developed genetically enhanced cord-blood derived immune cells to target B-cell malignancies, boosting persistence and embedding a suicide gene. The engineered natural killer cells showed improved efficiency in killing cancer cells and extended survival in mouse models.
The Oncology Drugs Advisory Committee recommends approval of CAR T cell therapy for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL), saving lives of children and young adults. Stand Up To Cancer and St. Baldrick's Foundation committed millions to the development of this life-saving treatment.
A new type of immunotherapy using CAR T cells targeting B-cell maturation protein (BCMA) has shown promising results in treating multiple myeloma, achieving a 100% objective response rate and 94% clinical remission. Most patients experienced mild side effects, with only one case of disease progression among those in complete response.
A phase 1 pilot study is examining the feasibility and safety of administering a second T-cell product to increase the long-term persistence of CAR T cells. The goal is to reduce the relapse rate, which is currently around 50%.
Researchers developed a biopolymer delivery system combining CAR T cells and STING agonists to eliminate tumors more effectively than CAR T cell therapy alone. The method improved targeting of solid tumors, reducing metastasis, and providing promising support for combined immunotherapy approaches.
Researchers Michael Farwell and Gregory L. Beatty will receive $750,000 to develop a new tracking system for CAR T cells using PET imaging, improving the effectiveness of cancer treatments. They aim to make immunotherapies more effective in metastatic liver disease.
Researchers found that activating CARs reduced biliary cholesterol levels, preventing stone formation. The study suggests CARs may play a role in maintaining cholesterol homeostasis, potentially offering a novel approach to prevent or treat cholesterol gallstone disease.
Researchers have successfully imaged the two dominant melanin molecules using a refined Raman-based technique, CARS microscopy. This breakthrough could lead to new understandings and early detection of melanoma, particularly in cases where pheomelanin is present.
Researchers at Memorial Sloan Kettering Cancer Center have developed more potent CAR T cells using CRISPR/Cas9 genome editing, which can kill tumor cells longer and resist exhaustion. This breakthrough could lead to safer and more effective use of immunotherapy in cancer patients.
The phase I trial of CAR-T therapy with axicabtagene ciloleucel resulted in a durable complete remission rate of 43% among highly refractory diffuse large B-cell lymphoma patients. The treatment showed promising clinical activity, with an overall response rate of 71%, and manageable toxicity.
The study found that KTE-C19 induced a significant response rate in patients with diffuse large B-cell lymphoma, with 76% overall response and 47% complete remission. Serious adverse events were reported, but the team developed guidelines to manage side effects across multiple institutions.
The phase 2 portion of the ZUMA-1 study using KTE-C19 CAR-T therapy achieved complete remission in all 6 patients with refractory primary mediastinal B-cell lymphoma or transformed follicular lymphoma, with manageable toxicities. The treatment was well-tolerated, with grade 3 adverse events occurring in 17% of patients.
A small early-phase trial of CAR T-cell immunotherapy developed at Fred Hutchinson Cancer Center showed a high percentage of patients with chronic lymphocytic leukemia (CLL) experienced tumor shrinkage or disappearance after treatment. The therapy targeted CD19, a molecule found on the surface of CLL cells.
A global multicenter trial of CAR T cells reported high complete response rates (82%) in children and young adults with relapsed or refractory acute lymphoblastic leukemia. A single-center pilot trial using humanized CAR T cells showed comparable effectiveness with reduced side effects.
Researchers from Penn Medicine present early results from studies of CAR T cell therapy for multiple myeloma and relapsed/refractory acute lymphoblastic leukemia, showing high efficacy and safety profiles. The findings build on the team's work in CAR T cell therapies dating back to 2010.
Researchers from MIPT and JINR use intersecting laser beams to test protein crystal quality and spot peculiar protein features. This method improves the accuracy of detecting small crystals, essential for studying membrane proteins.
A new approach to treat cancer involves depleting CAR T cells after treatment, permanently restoring healthy B cell levels. Researchers created CD19-targeting CAR T cells with an additional EGFR targeting mechanism, eliminating tumors and reversing B cell aplasia in mice.
In a phase 1 clinical study of 32 participants with advanced B cell non-Hodgkin lymphoma, immunotherapy with defined subsets of T cells showed strong antitumor activity. The therapy was found to be more effective when combined with specific ratios of CD4 and CD8 CAR-T cells and pretreatment chemotherapy regimen.
Researchers at Fred Hutchinson Cancer Center report promising results from an early-phase study of CAR T cell treatment, achieving complete remission in 50% of patients. The study's findings suggest that a defined composition of CAR T cells can increase efficacy while minimizing toxic side effects.
Engineered CAR T cells targeting multiple tumor antigens show improved anti-tumor activity and survival rates in an animal model of glioblastoma. This approach could lead to more effective immunotherapies for certain types of cancer.
Scientists at the University of Pennsylvania have developed a new therapy that selectively targets antibody-producing cells causing autoimmune disease, without harming the rest of the immune system. The treatment uses engineered T cells with an artificial receptor to bind to and destroy harmful B cells producing antibodies.
Researchers develop CAR T cell therapy targeting a specific glycopeptide found on cancer cells but not normal cells, showing promise in treating leukemia and pancreatic cancer in mice. The therapy demonstrates improved survival rates and potential for broad applicability to various cancers.
Researchers developed a new CAR T cell therapy that targets solid tumors using an antibody-carbohydrate combination. The therapy was shown to be effective in mouse models of pancreatic cancer, with increased survival rates and no damage to normal human cells.
Researchers found that both dose and infusion regimen are crucial to maximize response and safety for CAR T cells. Optimal doses and regimens showed high complete remission rates, with no treatment-related deaths in some cases.
Researchers at Purdue University have developed a new approach to engineered T-cell cancer treatment, using adaptors to control the immune cells' activity. The technology has been tested in animal models and shows promise for treating multiple types of cancer simultaneously by targeting different tumor-specific proteins.
A clinical trial has shown that 27 of 29 advanced leukemia patients went into remission after their T cells were genetically engineered to fight cancer. The therapy, known as CAR T-cell therapy, uses a synthetic receptor molecule to empower the T cells to recognize and kill cancer cells.
Researchers from Penn Medicine and Harvard University have developed a novel CAR T cell therapy that targets glioblastoma, a deadly brain cancer. The phase I trial has shown promising results, with patients experiencing significant expansion of engineered T cells in their blood and infiltration of tumors.
Researchers at Nagoya University developed a novel immunotherapy using genetically engineered T cells that target podoplanin, a key protein associated with GBM progression. This treatment successfully arrested tumor growth in 60% of mice and demonstrated promise for treating patients with relapsed or resistant tumors.
Researchers have achieved unprecedented response rates of up to 93% and durable remissions of over two years in children with relapsed/refractory acute lymphoblastic leukemia. Similarly, patients with non-Hodgkin lymphoma responded well to personalized cellular therapy, with complete remissions seen in 14 patients.
Researchers have developed a molecular 'on switch' to control T cell actions in cancer therapy, allowing for sharper reduction of severe side effects. The innovation enables doctors to precisely manage immune responses using a controller drug that flips cells into an active status.
Researchers developed a new system to fine-tune the affinity of CAR T cells, enabling them to selectively target cancer cells. The newly engineered cells showed more potent reactivity against tumor cells expressing high levels of specific proteins.
Researchers engineered CAR T cells to preferentially target cancer cells expressing high amounts of epithelial growth factor receptor (EGFR), while sparing normal cells. The modified cells were selectively activated only in response to cancer cells, demonstrating improved safety and efficacy in treating solid tumors.
A review article highlights barriers to overcome in CAR T cell therapy for lymphoma, including physical barriers and immunosuppression. The study explores factors related to tumor biology and immunology compared to treatment response in patients with lymphoma.
A preclinical study by the University of Pennsylvania School of Medicine found engineered T cells to be both safe and effective at controlling tumor growth in mice with glioblastoma. The CAR T cells target a mutation in the epidermal growth factor receptor protein called EGFRvIII, found on about 30% of glioblastoma patients' tumor cells.
Researchers have successfully treated patients with advanced CD19-positive hematologic malignancies using CAR T cells, achieving complete remission in some cases. The study used the Sleeping Beauty non-viral transduction system to modify T cells, demonstrating further promise in treating lymphoid malignancies.
The Phase 1-2a clinical trial demonstrated a 92% objective response rate, including complete remissions in eight patients and partial remissions in four patients. Four out of seven evaluable patients with chemotherapy-refractory DLBCL achieved complete remissions, with durations ranging from 9 to 22 months.
A study at the University of Texas MD Anderson Cancer Center used the Sleeping Beauty gene transfer system to modify T cells and fight invasive Aspergillus fungus. The approach has implications for genetically modifying T cells to target carbohydrate antigens, broadening their application in treating pathogens and malignancies.
A new vascular homing peptide, CAR, selectively targets hypertensive pulmonary arteries to enhance the effects of existing vasodilators without systemic side effects. The peptide retains its activity when given sublingually, offering a potential breakthrough in PAH treatment.
Researchers have developed genetically engineered cell therapies demonstrating early efficacy and safety in patients with blood disorders. The treatments use a patient's own re-engineered cells to attack their disease, offering an innovative approach to precision medicine.
A new gene transfer strategy using modified human stem cells introduces chimeric antigen receptors to target tumor cells, leading to a persistent anti-tumor immune response. This approach has shown promise in treating blood cancers such as leukemia and lymphoma.
Researchers developed a dual CAR approach that allows engineered T cells to selectively target tumor cells while sparing normal tissue. This innovative approach uses two separate antigen-specificity proteins, one for starting and another for boosting the immune response.
Researchers report success of gene transfer therapy to turn patients' immune cells into cancer-fighting weapons. Three patients remain in full remission over two years after treatment, marking first successful demonstration of the approach.
Assistant Professor Navin Varadarajan will use a novel research tool to study individual CAR T cells and determine their properties relating to their ability to fight cancer. The goal is to identify which modified T cells are most effective at fighting cancer, allowing researchers to design better treatment regimens.
Researchers found that infants' cortisol levels remain stable upon waking and after naps, unlike adults. This discovery may influence how infants handle stress and react to care from their mothers later in life.
The CARING CARS project aims to make driving safer by developing an innovative sensor network that monitors a driver's vital signs and responds accordingly. The system detects fatigue, emotional state, and other factors to provide alerts and assistance in emergency situations.
A new method for molecular imaging in cells using CARS technique reduces power levels while increasing speed, enabling detailed molecular maps without damaging cells. This breakthrough opens the door for widespread use of vibrational spectroscopy in biology and clinical diagnosis.
A new study from the Children's Hospital of Philadelphia has found that eliminating a specific cell receptor, CAR, prevents infection by a common virus that causes serious diseases in humans. The researchers used genetically engineered mice to demonstrate the critical role of CAR in coxsackievirus infections.
Researchers at MDC Berlin-Buch discovered a mechanism to prevent viral myocarditis by blocking the Coxsackie-adenovirus-receptor. Genetically engineered mice without this receptor were protected from cardiac infection caused by the Coxsackievirus, showing that autoimmune response may not be the primary cause of disease process.
Researchers have discovered a molecular mechanism underlying cardiac arrhythmia, revealing that a virus receptor plays a crucial role in regulating heart rhythm. The study found that the receptor is essential for normal heart function and its absence or dysfunction leads to arrhythmia.
Researchers have discovered a mechanism to overcome the resistance of human glioblastoma multiforme cells to growth factor inhibitors by blocking inhibitor of apoptosis proteins. Combining drugs targeting IAPs with RTK inhibitors showed enhanced efficacy in inhibiting tumor growth. Additionally, targeting liver CB1 receptors may provid...
Researchers at Memorial Sloan-Kettering Cancer Center have developed a new therapy using re-engineered human T cells that can recognize and kill cancerous B cells. The treatment showed promising results in mice, eradicating cancer in 44% of those with human ALL tumors.
Purdue researchers used CARS imaging to study how the myelin sheath is degraded by lysophosphatidylcholine. The findings suggest that calcium ions activate enzymes that break down proteins and molecules in the myelin, leading to its degradation. This research may lead to new treatments for multiple sclerosis.
The Clemson Inflatable Fabric Airlock, developed in collaboration with NASA, boasts a two-layer fabric design that eliminates seams for added strength. The airlock has withstood a terrestrial tensile force of over 675,000 pounds at four atmospheres of internal pressure.
A study reveals a new mechanism in acetaminophen toxicity and suggests blocking the CAR receptor as a potential approach to treating liver damage. Researchers found that CAR plays a critical role in mediating acetaminophen's toxic effects, and a drug called androstanol shows promise in reversing this effect.